160 related articles for article (PubMed ID: 26028942)
21. Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis.
Shinkai A; Saito W; Hashimoto Y; Ishida S
BMC Ophthalmol; 2019 Dec; 19(1):267. PubMed ID: 31888549
[TBL] [Abstract][Full Text] [Related]
22. Risk factors in patients with macular telangiectasia 2A in an Asian population: A case-control study.
Elias A; Gopalakrishnan M; Anantharaman G
Indian J Ophthalmol; 2017 Sep; 65(9):830-834. PubMed ID: 28905826
[TBL] [Abstract][Full Text] [Related]
23. Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3.
Clemons TE; Gillies MC; Chew EY; Bird AC; Peto T; Wang JJ; Mitchell P; Ramdas WD; Vingerling JR;
Ophthalmic Epidemiol; 2013 Apr; 20(2):109-13. PubMed ID: 23510315
[TBL] [Abstract][Full Text] [Related]
24. STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS IN A PATIENT WITH MACULAR TELANGIECTASIA TYPE 2.
Falb T; Malle EM; Haas A; Weger M; Wedrich A
Retin Cases Brief Rep; 2021 May; 15(3):335-338. PubMed ID: 30063580
[TBL] [Abstract][Full Text] [Related]
25. [Inefficacy of aflibercept in the treatment of idiopathic macular telangiectasia type 2 without neovascularization].
Bénichou J; Soler V; Denis D; Matonti F
J Fr Ophtalmol; 2017 Sep; 40(7):547-551. PubMed ID: 28803666
[TBL] [Abstract][Full Text] [Related]
26. Relevance of multicolor imaging, its component channels, and fundus autofluorescence in describing macular telangiectasia type-2 (MacTel) lesion characteristics.
Chandran K; Giridhar A; Desai S; Gopalakrishnan M; Indu VP; Sivaprasad S
Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S125-S134. PubMed ID: 38131554
[TBL] [Abstract][Full Text] [Related]
27. Self-Supervised Learning for Improved Optical Coherence Tomography Detection of Macular Telangiectasia Type 2.
Gholami S; Scheppke L; Kshirsagar M; Wu Y; Dodhia R; Bonelli R; Leung I; Sallo FB; Muldrew A; Jamison C; Peto T; Lavista Ferres J; Weeks WB; Friedlander M; Lee AY;
JAMA Ophthalmol; 2024 Mar; 142(3):226-233. PubMed ID: 38329740
[TBL] [Abstract][Full Text] [Related]
28. "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia.
Sallo FB; Peto T; Egan C; Wolf-Schnurrbusch UE; Clemons TE; Gillies MC; Pauleikhoff D; Rubin GS; Chew EY; Bird AC;
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6145-52. PubMed ID: 22899757
[TBL] [Abstract][Full Text] [Related]
29. CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2.
Jacob J; Krivosic V; Paques M; Tadayoni R; Gaudric A
Retina; 2016 Mar; 36(3):545-51. PubMed ID: 26418443
[TBL] [Abstract][Full Text] [Related]
30. Overlap between telangiectasia and photoreceptor loss increases with progression of macular telangiectasia type 2.
Micevych PS; Lee HE; Fawzi AA
PLoS One; 2019; 14(10):e0224393. PubMed ID: 31658282
[TBL] [Abstract][Full Text] [Related]
31. Morphologic characteristics of idiopathic juxtafoveal telangiectasia using spectral-domain and polarization-sensitive optical coherence tomography.
Schütze C; Ahlers C; Pircher M; Baumann B; Götzinger E; Prager F; Matt G; Sacu S; Hitzenberger CK; Schmidt-Erfurth U
Retina; 2012 Feb; 32(2):256-64. PubMed ID: 21926940
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of macular hole surgeries for macular telangiectasia type 2.
Karth PA; Raja SC; Brown DM; Kim JE
Retina; 2014 May; 34(5):907-15. PubMed ID: 24270919
[TBL] [Abstract][Full Text] [Related]
33. The longitudinal impact of macular telangiectasia (MacTel) type 2 on vision-related quality of life.
Lamoureux EL; Maxwell RM; Marella M; Dirani M; Fenwick E; Guymer RH
Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2520-4. PubMed ID: 21217104
[TBL] [Abstract][Full Text] [Related]
34. Associations between autofluorescence abnormalities and visual acuity in idiopathic macular telangiectasia type 2: MacTel project report number 5.
Balaskas K; Leung I; Sallo FB; Clemons TE; Bird AC; Peto T
Retina; 2014 Aug; 34(8):1630-6. PubMed ID: 24743635
[TBL] [Abstract][Full Text] [Related]
35. The prevalence of type 2 idiopathic macular telangiectasia in two African populations.
Sallo FB; Leung I; Mathenge W; Kyari F; Kuper H; Gilbert CE; Bird AC; Peto T;
Ophthalmic Epidemiol; 2012 Aug; 19(4):185-9. PubMed ID: 22364548
[TBL] [Abstract][Full Text] [Related]
36. SD-OCT stages of progression of type 2 macular telangiectasia in a patient followed for 3 years.
Coscas G; Coscas F; Zucchiatti I; Bandello F; Soubrane G; SouÏed E
Eur J Ophthalmol; 2013; 23(6):917-21. PubMed ID: 24030540
[TBL] [Abstract][Full Text] [Related]
37. Optical coherence tomography of idiopathic juxtafoveolar telangiectasia.
Albini TA; Benz MS; Coffee RE; Westfall AC; Lakhanpal RR; McPherson AR; Holz ER
Ophthalmic Surg Lasers Imaging; 2006; 37(2):120-8. PubMed ID: 16583633
[TBL] [Abstract][Full Text] [Related]
38. Macular telangiectasia type 2 accompanied by solitary retinal astrocytic hamartoma (case report).
Pencak M; Krasny J; Veith M; Vokrojova M
BMC Ophthalmol; 2016 Nov; 16(1):200. PubMed ID: 27835961
[TBL] [Abstract][Full Text] [Related]
39. [Idiopathic macular telangiectasia: clinical appearance, imaging and treatment].
De Bats F; Denis P; Kodjikian L
J Fr Ophtalmol; 2013 Feb; 36(2):164-71. PubMed ID: 23200165
[TBL] [Abstract][Full Text] [Related]
40. Genetic Penetrance of Macular Telangiectasia Type 2.
Ronquillo CC; Wegner K; Calvo CM; Bernstein PS
JAMA Ophthalmol; 2018 Oct; 136(10):1158-1163. PubMed ID: 30098143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
